Schwartzberg on Bringing Seminal Observations on AR From Bench to Bedside in ER+ Breast Cancer

Dr. Schwartzberg discusses the rationale to evaluate enobosarm in AR-positive, ER-positive advanced breast cancer, phase 2 data with the agent, and expectations for the ongoing phase 3 ARTEST trial in this population.